{
    "nct_id": "NCT05011383",
    "official_title": "High-dose Testosterone in Men With Metastatic Castration-resistant Prostate Cancer and ATM or CDK12 Deficiency",
    "inclusion_criteria": "* Signed informed consent form (ICF) providing agreement to adhere to the dosing schedule, report for all trial visits and authorization, use and release of health and research trial information\n* Male age > 18 years\n* Histologically or cytologically confirmed adenocarcinoma of the prostate\n* Ongoing gonadal androgen deprivation therapy with gonadotropin-releasing hormone (GnRH) analogues, antagonists or orchiectomy. Patients who have not had an orchiectomy must be maintained on effective GnRH analogue/antagonist therapy\n* Castration resistant prostate cancer as defined by serum testosterone < 50 ng/ml and one of the following:\n\n  * PSA level of at least 2 ng/ml that has risen on at least 2 successive occasions at least 1 week apart.\n  * Evaluable disease progression by modified RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)\n  * Progression of metastatic bone disease on bone scan with > 2 new lesions\n* Presence of metastatic disease on bone or CT scan\n* Patients must have progressed on 1 next-generation AR-signaling inhibitor (e.g. abiraterone, enzalutamide, apalutamide, darolutamide, etc.).\n* Asymptomatic or minimal cancer related symptoms\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of < 2\n* Presence of inactivating mutations in ATM, CDK12 or CHEK2 as determined by a CLIA level assay for DNA sequencing.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Currently receiving active therapy for other neoplastic disorders will not be eligible.\n* Histologic evidence of small cell carcinoma (morphology alone - immunohistochemical evidence of neuroendrocrine differentiation without morphologic evidence is not exclusionary)\n* Known parenchymal brain metastasis\n* Liver metastases\n* Active or symptomatic viral hepatitis or chronic liver disease AST or ALT > 2.5 x ULN or total bilirubin > ULN (unless Gilbert's syndrome is the etiology of hyperbilirubinemia).\n* Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction measurement of <35 % at baseline\n* Patients with pain attributable to their prostate cancer and requiring the use of opioids.\n* Tumor causing urinary outlet obstruction that requires catheterization for voiding. Patients that require catheterization to void secondary to benign strictures or other non-cancer causes will be permitted to enroll.\n* Presence of dementia, psychiatric illness, and/or social situations limiting compliance with study requirements or understanding and/or giving of informed consent.\n* Any condition(s), medical or otherwise, which, in the opinion of the investigators, would jeopardize either the patient or the integrity of the data obtained.",
    "miscellaneous_criteria": ""
}